56 results about "Anti-Herpes simplex virus IgG" patented technology

The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.

The invention relates to a pharmaceutical composition with dammarane-type tetracyclic triterpene compound as an active component and an application thereof to the pharmaceutical field. Panax notoginseng is separated to obtain three dammarane-type tetracyclic triterpene compounds as shown in the following structural formula, in vitro pharmacological experiments show that the pharmaceutical composition has good in vitro inhibitory activity for herpes simplex virus type I and can be applied to the preparation of medicines for resisting herpes simplex virus type I and is used for treating herpetic keratitis, encephalitis, pneumonia, ulcerative stomatitis, blister and the like caused by herpes simplex virus type I.

An extract of fig leaf is prepared from the fig leaf through extracting in water or alcohol. Its can be used for preparing the medicines to kill the herpes simplex virus and the frequently encountered pathogenic bacteria.

The invention relates to the technical field of biology, and discloses anti-herpes simplex virus polypeptide and its application. Tests show that the anti-herpes simplex virus polypeptide has a high efficiency inhibition effect to the herpes simplex virus propagation, and the anti-herpes simplex virus polypeptide is used for producing the medicines for treating and preventing diseases related to herpes simplex. The invention provides a medicinal preparation which takes the anti-herpes simplex virus polypeptide as the effective component for treating the herpes caused by the herpes simplex virus, and has a obvious effectiveness for treating herpes, the effective rate for treating herpes simplex, labial herpes and genital herpes can reach to 100%. And the anti-herpes simplex virus polypeptide has low recurrence rate after heal and no toxic side effect.

The present invention belongs to the field of medicine and gene engineering technology, and is especially one kind of polyepitope DNA vaccine resisting herpes virus-2 infection and its preparation process. The present invention connects gB, gC and gD of HSV-2 and the main antigen epitope region plus interval sequence of immediate early protein of ICP27 serially to eukaryotic expression vector pcDNA3.1 to obtain the DNA vaccine HV-pcDNA3.1. The DNA vaccine may be used in preventing and treating HSV-2 infected diseases, such as genital herpes, etc. The DNA vaccine has the features of high specificity, high protection and simple preparation process.

The invention discloses a pharmaceutical composition for resisting herpes simplex virus and its preparing process, wherein the composition is prepared from coptis root, gentian root, pipewort, baras camphor by a predetermined weight ratio, the obtained active constituent has the actions of reducing fever, purging the intense heat and detoxicating. The composition can be prepared into eye drops, nose spray and electuary.

The invention discloses houttuynoids and a preparation method and application thereof. The houttuynoids have a structural formula as represented by formula (I) which is described in the invention; in the formula (I), R1 is represented by formula (I), formula (II), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX) or formula (X) as described in the invention, and R2 is hydrogen or is represented by formula (XI), formula (XII), formula (XIII) or formula (XIV) as described in the invention. 12 houttuynoids are separated from Saururaceae Houttuynia cordata Thunb. and are all furan-flavones with novel structures. An in-vitro anti-herpes simplex virus activity screening system is used for evaluating activity of the houttuynoids, and it is found that the houttuynoids can effectively inhibit a herpes simplex virus; thus, the houttuynoids have effects on preventing and treating herpes simplex virus infection, can be applied to preparation of drugs used for resisting the herpes simplex virus and have good research and development prospects.

The invention discloses a preparing method of a peroxy-ergosterol compound. The preparing method comprises the steps of smashing blocks of poria cocos, conducting reflux extraction 3-5 times, recycling an extracting solution to obtain extract, adding water to disperse the extract, and using ethyl acetate to conduct extraction 5-10 times to obtain a crude extract; using dynamic axial industrially-prepared chromatography to separate the crude extract to obtain a relatively pure product of peroxy-ergosterol; recrystallizing the obtained relatively pure product of peroxy-ergosterol to obtain peroxy-ergosterol of which the purity is larger than 98%. The invention further discloses application of the peroxy-ergosterol compound in preparing a drug for resisting herpes simple virus I. The multiplication of HSV-I in cells can be inhibited, the multiplication of the virus can be 100% inhibited when the concentration of peroxy-ergosterol is 40.12Mug / mL, and the selection index of peroxy-ergosterol in HSV-I is 7.5. As is shown, peroxy-ergosterol can be applied to preparing the drug for resisting the herpes simplex virus-I(HSV-I).

The invention relates to a method for preparing carrageenin-sulfate oligosaccharide with antiviral activity, which is characterized in that culture medium for beta-glucanase production is prepared, marine cellulophaga is inoculated; kappa-carrageenin crude digestive enzyme liquid is fermented and extracted; additionally, the kappa-carrageenin is dissolved in distilled water and undergoes enzymatic hydrolysis reaction after the kappa-carrageenin crude digestive enzyme liquid is added; the enzymatic hydrolysis reaction liquid is converted into concentrated liquid after the rotary evaporation; enzymatic hydrolysis oligosaccharide fragment is collected by precipitating organic solvent; and then sulfate modification is carried out on the enzymatic hydrolysis oligosaccharide fragment and carrageenin-sulfate oligosaccharide is obtained. The invention has the advantage that the step combining enzymatic hydrolysis and the sulfate modification is applied, so that the preparation process is simple, the product yield is high, the product quality is stable and active groups during the preparation are not damaged, in addition, the product has the antiviral activity, in particular to the obvious antiviral activity against herpes simplex virus.

The invention discloses an anti-HSV active polypeptide of Tibetan Pi scorpion and application thereof. According to the invention, through the methods of molecular biology and chemical synthesis, the anti-HSV active polypeptide of Tibetan Pi scorpion, AHSVP1, is obtained; the antiviral activity of AHSVP1 to HSV is determined by using the method of plaque array. The invention also discloses externally used anti-HSV gel which is prepared from 0.5 wt % of the medicine AHSVP1 and 1.5 wt % of a carboxymethylcellulose matrix. The gel provided in the invention is used for anti-HSV infection; the products of the gel are stable and are suitable for storing and transporting. A production process for the gel has the advantages of simple and reasonable design, low production cost and suitability for mass industrial production.

The invention relates to a Thalassia hemprichii extract, and a preparation method and an application thereof. The preparation method comprises soaking Thalassia hemprichii with an organic solvent to obtain a crude extract, performing sequential liquid extraction of the crude extract with chloroform or ethyl acetate and n-butanol, collecting water layer, performing macroporous resin normal pressure column chromatography, eluting with a water-methanol solvent system or a water-ethanol solvent system, collecting methanol or ethanol eluate, rinsing with methanol, and collecting component indissoluble in methanol and having strong ultraviolet absorption at ultraviolet wavelength of 254nm to obtain the product. The inventive Thalassia hemprichii extract has strong anti-herpes simplex virus (HSV-1) activity, in vitro anti-CVB3 virus activity, insect antifeedant activity, and strong bryozoan (Bugula neritina) larvae attachment inhibitory activity; and can be used for preparing antiviral drugs, biological pesticides and ocean green anti-fouling agents.

The invention relates to an application of germacrone in preparing an HSV (Herpes Simplex Virus) resisting medicine. By taking HSV-1 (Herpes Simplex Virus type 1) and HSV-II (Herpes Simplex Virus type 2) strains and Vero (Rabies Purified Vaccine for Human Use) cells as experimental subjects, the HSV resisting activity of the germacrone is researched. The result shows that the germacrone has the good HSV resisting activity. As the germacrone is used for preparing the HSV treating / preventing medicine, an important development and application prospect for preventing and treating diseases caused by the HSV infection is achieved.

The invention discloses application of Eucheuma gelatinae polysaccharide in preparing anti-herpes simplex virus medicament. The Eucheuma gelatinae polysaccharide has mean molecular weight of 1,000-100,000. The Eucheuma gelatinae polysaccharide provided by the invention has independent anti-herpes simplex virus effect.

A polygonalectin II protein is prepared from siberian solomonseal rhizome through preparing coarse product, affinity column separating and purifying byuse of mannose-Sepharose 4B as absorbent, purifying by molecular sieve Sephacyl S-100, eluting with physiologic saline, collecting, dialyzing for removing salt, and freeze drying. It can suppress the activity of HSV, so it can be used to treat herpes simplex.

The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.

The invention provides a new hydrochloric acid 2-(1-ethyl propyl) moroxydine which can be obtained by chemical synthesis and has the advantages of low price of needed raw materials, easily obtained raw materials, simple and convenient preparation method, higher yield and suitability for industrialized production. The pharmacological activity experiment proves that compared with hydrochloric acid moroxydine, the hydrochloric acid 2-(1-ethyl propyl) moroxydine has the remarkably enhanced activity of in vivo resisting hepatitis B virus, hepatitis C virus, influenza virus, pneumovirus and herpes simplex virus, and the toxicity is one time lower than that of the hydrochloric acid moroxydine. Therefore, the new hydrochloric acid 2-(1-ethyl propyl) moroxydine can be applied to prepare antiviral drugs, especially anti-flu drugs, hepatitis C resisting drugs, hepatitis B resisting drugs, pneumovirus resisting drugs and herpes simplex viral keratitis resisting drugs.

The invention discloses an application of a compound in preparation of an antiviral drug. In one embodiment of the invention, the in-vitro anti-herpes simplex virus I activity of dihydromyricetin is verified through experiments, virus proliferation and related gene expression can be inhibited, the toxicity is relatively low, and a relatively high treatment index can be obtained. Meanwhile, it is proved that the anti-herpes simplex virus action mechanism of the dihydromyricetin is related to inhibition of TLR9-dependent inflammatory response pathways by the dihydromyricetin. In one embodiment of the invention, the dihydromyricetin is disclosed to have potential value of serving as the novel anti-herpes simplex virus drug, and can be applied to preparation of the anti-herpes simplex virus drug.

The invention belongs to the field of pharmacy, and relates to application of wogonin in preparing medicine for resisting a herpes simplex virus. An experiment verifies that wogonin has a high activity of resisting the herpes simplex virus in an in-vitro experiment and can inhibit the expression of virus structure protein gD in mRNA transcription and the protein level; an in-vitro toxicity experiment of wogonin finds that the flavone type compound has low toxicity to cells of the human and African green monkeys and can obtain a high treatment index; therefore, wogonin has potential value as novel medicine resisting the herpes simplex virus and can be applied to preparing the medicine for resisting the herpes simplex virus.

The invention belongs to the pharmaceutical field of traditional Chinese medicine, relating to application of a traditional Chinese medicine extract of orsythoside A in the preparation of a medicament for treating herpes simplex. In the invention, the effect of the orsythoside A against herpes simplex viruses is researched through in vitro and in vivo mouse tests. Experimental results show that the orsythoside A has obvious inhibiting effect on the herpes simplex II-type viruses of the mouse in vitro and in vivo, and the effect and dosage are in a response relationship.

The invention relates to a recombinant HSV (Herpes Simplex Virus) amplicon vector and application thereof. By using two replication deficient adenoviruses respectively carrying Cre and an operative linked component loxP-HSVoriS-pac-transgenic expression box-loxP, a novel HSV amplicon vector is recombined in a coinfection cell. Being different from the traditional HSV amplicon vector taking bacterial plasmids as a skeleton, the amplicon vector does not contain a bacteria copying sequence (colEorigin) and a resistance gene component and only contains oriS of HSV, a pac sequence and a transgenic expression box. The recombinant HSV amplicon vector disclosed by the invention is used for preparing a novel HSV amplicon vector, which does not contain the bacterial gene component and is used for various types of transgenic researches and tumour gene treatments, and preparing an adenovirus treatment preparation for specific anti-HSV virus and related diseases. The HSV amplicon vector recombined by the replication deficient adenovirus of the preparation in cells replicates itself by using infected wild HSV virus and competitively inhibits or permanently expresses the antiviral genes so as to inhibit replication of wild HSV virus. Therefore, the recombinant HSV amplicon vector can be used for resisting HSV infection and treating related diseases thereof.

The invention discloses an application of fresh euphorbia helioscopia juice in the preparation of a medicine for resisting herpes simplex virus. A large number of experimental screening and experimental results prove that the fresh euphorbia helioscopia juice has a significant effect of inhibiting the cytopathic effect caused by the herpes simplex virus in vitro. The fresh euphorbia helioscopia juice has low toxicity and can lead to slight adverse reactions. The euphorbia helioscopia resources are wide and easy to obtain, have low cost and wide application prospect, can be developed sustainably and are expected to be developed into the medicine for resisting the herpes simplex virus.

The invention relates to a new carbazole alkaloid represented by the formula (1), and also relates to a preparation method thereof and applications thereof. The alkaloid is characterized in that: crude extracts of an organic solvent of Antipathes dichotcma (Pallas) are extracted with ethyl acetate or chloroform after being suspended on water, an ethyl acetate layer or a chloroform layer is collected for carrying out the normal pressure silica gel column chromatography, the thin-layer chromatography is used for tracing and combination, and a chloroform-acetone solvent system in a volume ratio of 9:1 is used for elution, the collected Rf value is about 0.5 to 0.7, and compositions of ultraviolet absorption exist under the wavelength of 254nm of an ultraviolet lamp, a crude product is gained, and a pure product is obtained through the further purification. The carbazole alkaloid can be used for preparing medicines treating gastric cancers, liver cancers and anti-herpes simplex virus, and has the half inhibition concentration IC50 of 67.38mu g / mL and 73.65mu g / mL respectively to human gastric adenocarcinoma cell line SGC-7901 and human hepatoma cell Hep G2; and the IC50 value of the anti-herpes simplex HSV-I virus is 30.68mu g / mL.

The invention provides application of 1,2,3,4,6-penta-O-galloyl-b-D-glucose in preparing a medicine for resisting herpes simplex viruses, and in particular relates to application of the 1,2,3,4,6-penta-O-galloyl-b-D-glucose in preparing a medicine for resisting herpes simplex virus type 1. The 1,2,3,4,6-penta-O-galloyl-b-D-glucose has the function of preventing and treating cells infected by HSV-1, can also reduce the infectivity of the HSV-1 on MRC-5 cells, has the function of directly killing the HSV-1, and can reduce the activity of MRC-5 cells infected by the HSV-1; and the medicine for resisting the herpes simplex virus type 1 prepared by taking the 1,2,3,4,6-penta-O-galloyl-b-D-glucose as an effective ingredient has high suppression ratio on the herpes simplex virus type 1 within a safe dosage range, has strong function of preventing infection of the herpes simplex virus type 1, quickly cures patients, can relieve syndromes of infected patients, and has low toxicity and good stability.

The invention relates to novel application of chrysoeriol-7-beta-D-glucose-2''-sulfate shown in a formula (1) in preparation of herpes simplex virus resistant drug. The chrysoeriol-7-beta-D-glucose-2''-sulfate has no remarkable toxicity on a host Vero cell, the maximum toxicity-free concentration (TC0) of the chrysoeriol-7-beta-D-glucose-2''-sulfate to the Vero cell is more than 260mu g / mL, the inhibiting concentration (IC50) of the chrysoeriol-7-beta-D-glucose-2''-sulfate to HSV-1 (Herpes Simplex Virus) under a combined action manner is 3.772mu g / mL, the IC50 of the chrysoeriol-7-beta-D-glucose-2''-sulfate to the HSV-1 under a direct virus inactivating action manner is 0.084mu g / mL, the IC50 of the chrysoeriol-7-beta-D-glucose-2''-sulfate to the HSV-1 under an adsorption inhibiting action manner is 14.5mu g / mL, and the IC50 of the chrysoeriol-7-beta-D-glucose-2''-sulfate to the HSV-1 under a transfer inhibiting action manner is 12.06mu g / mL. The chrysoeriol-7-beta-D-glucose-2''-sulfate ensures that the virus cannot normally adsorb and penetrate in the cell through direct virus inactivation on the basis of preliminary guess, thereby blocking the HSV-1 infection outside the cell.

The invention discloses application of an acylthiourea compound in preparation of drugs for treating or preventing herpes simplex virus type 1 infection and belongs to the technical field of medicines. Proven by cytotoxicity and herpes simplex virus type 1 resisting activity results, the compound represented by a formula (I) has low toxicity to cells, has very good herpes simplex virus type 1 infection and replication resisting activity and high selectivity and can be applied to the preparation of the drugs for treating or preventing the herpes simplex virus type 1 infection.

The invention provides application of myricetin in preparing medicines and health products for preventing and treating diseases caused by herpes simplex virus. Experiments prove that the myricetin hasthe inhibitory activity on herpes simplex virus infection, has the activity of resisting HSV-1 and HSV-2, and has extremely low toxicity. The protein and mRNA expression of HSV-1 and HSV-2 were significantly inhibited by myricetin treatment. The action mechanism of the myricetin for resisting herpes simplex virus infection is that the myricetin directly interacts with HSV particles to interfere virus adsorption and virus-induced membrane fusion. Experiments prove that the myricetin can be developed into a novel target virus particle anti-HSV preparation and has good market application prospect.

The invention discloses an ophthalmic gel for treating herpes simplex viral keratitis. The ophthalmic gel comprises five raw and auxiliary materials of ganciclovir, honeys, a mixture of polyethylene glycol 400 and polyethylene glycol 4000 and polysorbate 80. The ophthalmic gel is prepared by using new technologies of modern preparations and has stronger anti-herpes simplex viral actions and more obvious pesticide effects of promoting healing, repairing and regenerating of cornea than similar products, and the ophthalmic gel is safe for patients to take during usage.

The invention discloses houttuynoids and a preparation method and application thereof. The houttuynoids have a structural formula as represented by formula (I) which is described in the invention; in the formula (I), R1 is represented by formula (I), formula (II), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX) or formula (X) as described in the invention, and R2 is hydrogen or is represented by formula (XI), formula (XII), formula (XIII) or formula (XIV) as described in the invention. 12 houttuynoids are separated from Saururaceae Houttuynia cordata Thunb. and are all furan-flavones with novel structures. An in-vitro anti-herpes simplex virus activity screening system is used for evaluating activity of the houttuynoids, and it is found that the houttuynoids can effectively inhibit a herpes simplex virus; thus, the houttuynoids have effects on preventing and treating herpes simplex virus infection, can be applied to preparation of drugs used for resisting the herpes simplex virus and have good research and development prospects.

The invention provides applications of anti-herpes simplex virus drug acyclovir in preventing or / and treating tardive diarrhea caused by one anti-tumor drug and intestinal dysfunctions caused by diarrhea, wherein the anti-tumor drug is irinotecan or active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) of irinotecan. The drug effect of acyclovir is clear; acyclovir is capable of relieving tardive diarrhea effectively, and protecting intestinal functions.